全文获取类型
收费全文 | 7464篇 |
免费 | 956篇 |
国内免费 | 72篇 |
专业分类
耳鼻咽喉 | 118篇 |
儿科学 | 140篇 |
妇产科学 | 91篇 |
基础医学 | 341篇 |
口腔科学 | 146篇 |
临床医学 | 772篇 |
内科学 | 1186篇 |
皮肤病学 | 132篇 |
神经病学 | 359篇 |
特种医学 | 244篇 |
外国民族医学 | 1篇 |
外科学 | 833篇 |
综合类 | 456篇 |
预防医学 | 2122篇 |
眼科学 | 183篇 |
药学 | 852篇 |
2篇 | |
中国医学 | 78篇 |
肿瘤学 | 436篇 |
出版年
2024年 | 11篇 |
2023年 | 149篇 |
2022年 | 229篇 |
2021年 | 355篇 |
2020年 | 382篇 |
2019年 | 453篇 |
2018年 | 445篇 |
2017年 | 412篇 |
2016年 | 287篇 |
2015年 | 293篇 |
2014年 | 491篇 |
2013年 | 640篇 |
2012年 | 407篇 |
2011年 | 466篇 |
2010年 | 365篇 |
2009年 | 311篇 |
2008年 | 334篇 |
2007年 | 355篇 |
2006年 | 291篇 |
2005年 | 253篇 |
2004年 | 248篇 |
2003年 | 207篇 |
2002年 | 197篇 |
2001年 | 165篇 |
2000年 | 119篇 |
1999年 | 96篇 |
1998年 | 84篇 |
1997年 | 55篇 |
1996年 | 67篇 |
1995年 | 38篇 |
1994年 | 25篇 |
1993年 | 38篇 |
1992年 | 27篇 |
1991年 | 39篇 |
1990年 | 27篇 |
1989年 | 24篇 |
1988年 | 22篇 |
1987年 | 13篇 |
1986年 | 10篇 |
1985年 | 10篇 |
1984年 | 14篇 |
1983年 | 5篇 |
1982年 | 8篇 |
1981年 | 3篇 |
1980年 | 7篇 |
1979年 | 7篇 |
1978年 | 1篇 |
1977年 | 2篇 |
1976年 | 4篇 |
1974年 | 1篇 |
排序方式: 共有8492条查询结果,搜索用时 46 毫秒
1.
《The Journal of hand surgery》2022,47(8):752-761.e1
2.
Ehsan Zarei Elmira Madarshahian Adeleh Nikkhah Soheila Khodakarim 《Journal of tissue viability》2019,28(2):70-74
Background and objective
Pressure ulcer (PU) is one of the important and frequent complications of hospitalization, associated with high treatment costs. The present study was conducted to determine the incidence of PU and its direct treatment costs for patients in intensive care unit (ICU) in Iran.Material and methods
In this retrospective study, medical records of 643 discharged patients from ICU of two selected hospitals were examined. The demographic and clinical data of all patients and data of resources and services usage for patients with PU were extracted through their records. Data analysis was done using logistic regression tests in SPSS 22 software. The cost of PU treatment was calculated for each grade of ulcer.Results
The findings showed that 8.9% of patients developed PU during their stay in ICU. Muscular paralysis (OR?=?5.1), length of stay in ICU (OR?=?4.0), diabetes (OR?=?3.5) age (OR?=?2.9), smoking (OR?=?2.1) and trauma (OR?=?1.4) were the most important risk factors of PU. The average cost of PU treatment varied from USD 12 for grade I PU to USD 66?834 for grade IV PUs. The total treatment costs for all studied patients with PU was estimated at USD 519?991.Conclusion
The cost of PU treatment is significant. Since the preventive measures are more cost-effective than therapeutic measures, therefore, effective preventive interventions are recommended. 相似文献3.
Cost‐Effectiveness and Cost‐Utility Analysis of Spinal Cord Stimulation in Patients With Failed Back Surgery Syndrome: Results From the PRECISE Study 下载免费PDF全文
Furio Zucco MD Roberta Ciampichini MSc Angelo Lavano MD Amedeo Costantini MD Marisa De Rose MD Paolo Poli MD Gianpaolo Fortini MD Laura Demartini MD Enrico De Simone MD Valentino Menardo MD Piero Cisotto MD Mario Meglio MD Luciana Scalone PhD Lorenzo G. Mantovani DSc 《Neuromodulation》2015,18(4):266-276
4.
5.
6.
目的 了解解放军总医院抗震颤麻痹药物的应用情况与用药趋势。方法 采用世界卫生组织(WHO)推荐的以限定日剂量(DDD)为指标的分析方法,对2015-2017年解放军总医院抗震颤麻痹药物的销售金额、用药频度(DDDs)、日均费用(DDC)及排序比(B/A)等进行统计分析。结果 普拉克索、多巴丝肼和恩他卡朋的用药金额始终处于前3位,普拉克索的用药金额逐渐上升,卡比多巴/左旋多巴的用药金额逐渐下降;DDDs排序列前2位的是多巴丝肼和司来吉兰,多巴丝肼的DDDs逐年上升,一直处于第1位;2015-2016年各种抗震颤麻痹药物的DDC较为稳定,2016-2017年各种抗震颤麻痹药物的DDC开始略有下降;除普拉克索和恩他卡朋的B/A始终小于1.00,其他抗震颤麻痹药物的B/A均在1.00以上波动。结论 解放军总医院抗震颤麻痹药物的使用较为合理,其中多巴丝肼、普拉克索和司来吉兰具有很好的市场前景。 相似文献
7.
Roberto De la Plaza Llamas Jos M Ramia 《World journal of gastroenterology : WJG》2020,26(21):2682-2690
Postoperative complications(PC) are a basic health outcome, but no surgery service in the world records and/or audits the PC associated with all the surgical procedures it performs. Most studies that have assessed the cost of PC suffer from poor quality and a lack of transparency and consistency. The payment system in place often rewards the volume of services provided rather than the quality of patients' clinical outcomes. Without a thorough registration of PC, the economic costs involved cannot be determined. An accurate, reliable appraisal would help identify areas for investment in order to reduce the incidence of PC,improve surgical results, and bring down the economic costs. This article describes how to quantify and classify PC using the Clavien-Dindo classification and the comprehensive complication index, discusses the perspectives from which economic evaluations are performed and the minimum postoperative follow-up established, and makes various recommendations. The availability of accurate and impartially audited data on PC will help reduce their incidence and bring down costs. Patients, the health authorities, and society as a whole are sure to benefit. 相似文献
8.
GIUSEPPE BORIANI MAURO BIFFI MAURIZIO RUSSO† MAURIZIO LUNATI‡ GIANLUCA BOTTO¶ ALESSANDRO PROCLEMER§ GIUSEPPE VERGARA WERNER RAHUE†† CRISTIAN MARTIGNANI RENATO RICCI† MASSIMO SANTINI† On Behalf of the SEARCH MI Registry Italian Investigators 《Pacing and clinical electrophysiology : PACE》2006,29(S2):S29-S34
Background: Large randomized trials show that in appropriately selected patients with left ventricular dysfunction, implantable cardioverter-defibrillators (ICDs) can improve overall survival at 2–5 years. Since direct implementation of the criteria used in the MADIT II and SCD-HeFT will lead to a marked rise in ICD implants, there is a growing fear that increased use of ICDs may cause a dramatic burden to health care systems. The ICD has traditionally been seen as an expensive form of treatment, which is difficult to accept at the first look. This is mainly due to the nonlinear character of the ICD investment, characterized by high initial expenditure, followed by a deferred pay-off in terms of clinical benefits. Cost-effectiveness analysis may help provide a different perspective on the problem of ICD cost, as may estimation of the daily cost of ICD treatment, assuming a time horizon of 5–7 years—a particularly interesting subject for further registry studies.
Methods and Results: Based on real expenditure data from 2002 to 2005, as recorded in the Search-MI Registry-Italian Sub-study of patients implanted on MADIT II indications, we estimated the daily costs associated with the device and leads. Over a 5–7 year time horizon, the average daily cost was estimated to be €4.60–€6.70. Translation of these figures into U.S. market conditions suggests a daily cost of around $7.90–$11.40.
Conclusions: These findings appear useful to help evaluate the affordability of ICD in comparison with other therapeutic options in a context of limited available economic resources. 相似文献
Methods and Results: Based on real expenditure data from 2002 to 2005, as recorded in the Search-MI Registry-Italian Sub-study of patients implanted on MADIT II indications, we estimated the daily costs associated with the device and leads. Over a 5–7 year time horizon, the average daily cost was estimated to be €4.60–€6.70. Translation of these figures into U.S. market conditions suggests a daily cost of around $7.90–$11.40.
Conclusions: These findings appear useful to help evaluate the affordability of ICD in comparison with other therapeutic options in a context of limited available economic resources. 相似文献
9.
A. Esquenazi 《European journal of neurology》2006,13(S4):27-34
Spasticity is a widespread, disabling form of muscle overactivity affecting patients with central nervous system damage resulting in upper motor neurone syndrome. There is a range of effective therapies for the treatment of spasticity (e.g. physical, anaesthetic, chemodenervation and neurolytic injections, systemic medication and surgery), but all therapies must be based on an individualized, multidisciplinary programme targeted to achieve patient goals. Appropriate therapy should be based on the extent and severity of spasticity, but spasticity and its consequences, regardless of presentation or cause, are commonly treated with systemic agents. This may be ill-advised as systemic treatment is associated with many undesirable effects. In particular, elderly patients with post-stroke spasticity are at risk from the central adverse effects of systemic medication (e.g. sedation and gait disturbance), which make them more susceptible to falling, with an associated increased risk of fracture. The rising costs of fracture care and its sequelae are fast becoming an international problem contributing to high healthcare expenditure. Botulinum toxin type-A (BoNT-A) treatment is highly effective for some of the more common forms of spasticity and muscle overactivity, and has a favourable profile when compared with systemic agents and other focal treatments. Therefore, the clinical benefits of BoNT-A treatment outweigh the apparent high costs of this intervention, showing it to be a cost-effective treatment. 相似文献
10.